Valvular & structural heart disease
Serum lipoprotein(a) and bioprosthetic aortic valve degeneration
Authors' conclusion
Serum lipoprotein(a) concentrations do not appear to be a major determinant or mediator of bioprosthetic aortic valve degeneration.
Study context
- Population
- Patients with bioprosthetic aortic valves (mean age 75 ± 7 years, 54% men)with Lp(a) available
- Participants
- 97 patients
- Comparison
- Highest vs lower tertiles of serum Lp
- Primary endpoint
- Association of serum Lp(a) with bioprosthetic aortic valve degeneration (echocardiography, computed tomography (CT) angiography, 18F-NaF positron emission tomography (PET))
Primary result
As reported in the abstract
Baseline peak aortic valve velocity (echocardiography) · baseline
P = 0.204
- Serum Lp(a) concentration, all participants (median)
- 19.9 (8.4-76.4) mg/dL
Further findings
| Outcome | Highest tertile | Lower tertiles | P value |
|---|---|---|---|
| Valve degeneration on CT angiography · baseline | 8 events | 12 events | P = 0.552 |
| 18F-NaF PET tissue-to-background ratio · baseline | median 1.13 (IQR 1.05–1.41) | median 1.17 (IQR 1.06–1.53) | P = 0.889 |
| Annualized change in peak aortic valve velocity · 2 years | 0.0 (IQR −0.1–0.2) m/s/year | 0.1 (IQR 0.0–0.2) m/s/year | P = 0.528 |
Development of structural valve degeneration · 2 years
- No differences between tertiles
Original publication
Serum lipoprotein(a) and bioprosthetic aortic valve degeneration. Eur Heart J Cardiovasc Imaging. Published 20 January 2023. doi:10.
Summarised from the published abstract; every number is checked against it